Literature DB >> 18226630

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Stefanie M Ueda1, Daniel S Kapp, Michael K Cheung, Jacob Y Shin, Kathryn Osann, Amreen Husain, Nelson N Teng, Jonathan S Berek, John K Chan.   

Abstract

OBJECTIVE: The purpose of this study was to determine factors responsible for the increasing number of deaths from corpus cancer over three time periods. STUDY
DESIGN: Data were collected from the Surveillance, Epidemiology and End Results database from 1988-2001. Kaplan-Meier and Cox proportional hazards regression analyses were performed.
RESULTS: Of 48,510 women with corpus cancer, there was an increase in the proportion of patients dying from advanced cancers (52.1% to 56.0% to 68.8%; P < .001), grade 3 disease (47.5% to 53.3% to 60.6%; P < .001), serous tumors (14.3% to 18.4% to 16.6%; P < .001), and sarcomas (19.1% to 20.4% to 27.2%; P < .001) over time. On multivariate analysis, older age, African American race, lack of primary staging procedures, advanced-stage, high-grade, and non-endometrioid histology were independent prognostic factors for worse survival.
CONCLUSION: Our data suggest that the increase in mortality in women with corpus cancer over the last 14 years may be related to an increased rate of advanced-stage cancers and high-risk histologies.

Entities:  

Mesh:

Year:  2008        PMID: 18226630     DOI: 10.1016/j.ajog.2007.08.075

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  69 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Authors:  Roberto Angioli; Stella Capriglione; Giuseppe Scaletta; Alessia Aloisi; Andrea Miranda; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2015-11-03

3.  Increased NUCKS expression is a risk factor for poor prognosis and recurrence in endometrial cancer.

Authors:  Tianbo Liu; Shu Tan; Ye Xu; Fanling Meng; Chang Yang; Ge Lou
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

4.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

5.  A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.

Authors:  Oliver Zivanovic; Lindsay M Jacks; Alexia Iasonos; Mario M Leitao; Robert A Soslow; Emanuela Veras; Dennis S Chi; Nadeem R Abu-Rustum; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

6.  Guess the case.

Authors:  William S Richardson; Lisa Bazzett; Thomas Kang
Journal:  Ochsner J       Date:  2010

7.  Factors associated with Type I and Type II endometrial cancer.

Authors:  Ashley S Felix; Joel L Weissfeld; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Faina Linkov
Journal:  Cancer Causes Control       Date:  2010-07-14       Impact factor: 2.506

8.  The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.

Authors:  Marina Frimer; June Y Hou; Thomas C McAndrew; Gary L Goldberg; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2012-09-20       Impact factor: 3.060

9.  A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.

Authors:  David M Hyman; Michael W Sill; Heather A Lankes; Richard Piekarz; Mark S Shahin; Mildred R Ridgway; Floor Backes; Meaghen E Tenney; Cara A Mathews; James S Hoffman; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2016-10-27       Impact factor: 5.482

10.  Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Authors:  Summer B Dewdney; Nora T Kizer; Abegail A Andaya; Sheri A Babb; Jingqin Luo; David G Mutch; Amy P Schmidt; Louise A Brinton; Russell R Broaddus; Nilsa C Ramirez; Phyllis C Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L Judson; Robert S Mannel; Shashikant B Lele; David M O'Malley; Paul J Goodfellow
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.